ING Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q2
Sell
-53,031
Closed -$2.52M 692
2014
Q1
$2.52M Buy
+53,031
New +$2.71M 0.01% 455
2013
Q3
Sell
-502,839
Closed -$17.5M 771
2013
Q2
$17.5M Buy
+502,839
New +$17.7M 0.09% 207

Other funds holding XBI

ING Group's XBI Position: Q2 2014 in Review

ING Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2014, closing a stake of 53,031 shares — an estimated $2.52M sold.

ING Group first reported a position in XBI in Q2 2013 and held it in 2 quarters. The position peaked at $17.5M in Q2 2013. 123 funds tracked by Wall St. Rank hold XBI as of Q2 2014.

  • ING Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2014 after selling out during the quarter.
  • ING Group sold 53,031 State Street SPDR S&P Biotech ETF shares in Q2 2014, an estimated $2.52M.
  • ING Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and held it in 2 quarters.
  • ING Group's State Street SPDR S&P Biotech ETF position peaked at $17.5M in Q2 2013.
  • 123 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2014.

Based on ING Group's 13F filing for Q2 2014, filed 14 Aug 2014.